## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.3% below STRENGTH zone (3.0-6.0%); PEG 3.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.06)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 10, Bearish: 0)

**1. GE HealthCare submits next-gen MRI tech to FDA, unveils new Allia system**
- Source: MassDevice | 20251201T203920 | Bullish | Relevance: 99%
- GE HealthCare announced the submission of its next-generation Signa MRI technology, including Signa Bolt and Signa Sprint systems, to the FDA for 510(k) clearance. These MRI systems feature AI-powered workflows, advanced imaging capabilities, and sustainable designs. Additionally, GE HealthCare unveiled the Allia Moveo, an image-guided solution designed to enhance mobility and flexibility in interventional suites.

**2. GE HealthCare introduces advanced imaging solutions powered by NVIDIA technology to support timely diagnoses and streamlined clinical workflows**
- Source: Business Wire | 20251202T140221 | Bullish | Relevance: 99%
- GE HealthCare has unveiled new imaging solutions integrating NVIDIA technology at RSNA 2025, aimed at improving diagnostic accuracy and clinical workflows. These innovations leverage NVIDIA's AI, high-performance computing, and simulation to enhance various modalities like CT, PET, cardiac, mammography, and ultrasound systems. The collaboration seeks to address challenges in medical imaging by reducing scan times, increasing diagnostic clarity, and potentially leading to more autonomous imaging workflows.

**3. GE HealthCare (Nasdaq: GEHC) expands NVIDIA-powered imaging across CT, MR, ultrasound**
- Source: Stock Titan | 20251202T090000 | Bullish | Relevance: 99%
- GE HealthCare is expanding its collaboration with NVIDIA, integrating NVIDIA's AI and accelerated computing technology into several new imaging solutions for CT, MR, and ultrasound. These innovations, showcased at RSNA 2025, aim to enhance diagnostic clarity, shorten scan times, and improve clinical workflows by processing large, complex datasets with speed and precision. The partnership addresses workflow efficiencies and patient care by leveraging advanced AI for image reconstruction, real-time enhancement, and the development of autonomous imaging concepts.

**4. GE HealthCare introduces two new MR systems, AI workflow platform at RSNA**
- Source: DOTmed | 20251130T204933 | Bullish | Relevance: 99%
- GE HealthCare has unveiled two new MR systems, SIGNA Bolt and SIGNA Sprint with Freelium, alongside a new AI-powered workflow platform, SIGNA One, at RSNA 2025. These new technologies aim to enhance efficiency, support sustainability, and improve diagnostic consistency in MRI, addressing the growing demand for imaging services and the radiologist shortage. Both systems are currently under FDA review.

**5. GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025**
- Source: The AI Journal | 20251130T145119 | Bullish | Relevance: 99%
- GE HealthCare (Nasdaq: GEHC) will showcase over 40 transformative innovations at RSNA 2025, building on more than a century of leadership in medical imaging. The company has invested over $3 billion in R&D since 2022 to address pressing healthcare challenges such as staff shortages and rising demand, leveraging AI and cloud-based solutions to enhance precision care. Key product unveilings include new photon counting CT systems, next-gen SIGNA MRI technology, advanced mammography, and AI-enabled workflow platforms, reflecting their commitment to innovation and clinician empowerment.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.6B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 16.3 |
| Current P/E | 17.6 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 5.8% to 1.3% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.7pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.75), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.34% (CS: 81) | Neutral |
| RSI_14 | 63.6 | Neutral |
| MACD Histogram | 0.75 | Bullish |
| vs SMA20 | 1.063x | Above |
| vs SMA50 | 1.067x | Above |
| vs SMA200 | 1.072x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.22
- **Stop Loss:** $76.06 (5.2% risk)
- **Target:** $84.38 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 240
- **Position Value:** $19,252.80
- **Portfolio %:** 19.25%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*